{"filing":{"accession_number":"0001140361-26-024269","cik":"0001444192","ticker":"GRCE","company_name":"Grace Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-05","report_date":null,"primary_document":"ef20075612_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1444192/000114036126024269/ef20075612_8k.htm"},"events":[{"id":3771,"run_id":3308,"accession_number":"0001140361-26-024269","anchor_item_number":"5.02","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.85,"summary":"Carrie D'Andrea, Vice President of Clinical Operations, is ceasing employment effective June 5, 2026. While the disclosure also mentions severance benefits and a consulting agreement, the principal disclosed action is the departure of a named officer. The filing centers on her separation from the Company, making exec_departure the most salient classification, though the compensation elements (severance and consulting fee) are secondary to the departure itself.","company_name":"Grace Therapeutics, Inc.","ticker":"GRCE","filing_date":"2026-06-05","items":[{"id":4785,"accession_number":"0001140361-26-024269","item_number":"5.02","item_title":null,"event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"Carrie D'Andrea, Vice President of Clinical Operations, is ceasing employment effective June 5, 2026. While the disclosure also mentions severance benefits and a consulting agreement, the principal disclosed action is the departure of a named officer. The filing centers on her separation from the Company, making exec_departure the most salient classification, though the compensation elements (severance and consulting fee) are secondary to the departure itself.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T20:10:31.912475+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":4785,"accession_number":"0001140361-26-024269","item_number":"5.02","item_title":null,"event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"Carrie D'Andrea, Vice President of Clinical Operations, is ceasing employment effective June 5, 2026. While the disclosure also mentions severance benefits and a consulting agreement, the principal disclosed action is the departure of a named officer. The filing centers on her separation from the Company, making exec_departure the most salient classification, though the compensation elements (severance and consulting fee) are secondary to the departure itself.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T20:10:31.912475+00:00","company_name":"Grace Therapeutics, Inc.","ticker":"GRCE","filing_date":"2026-06-05"}]}